SOX12 Antibody

What is SOX12 and what is its biological significance?

SOX12 (also known as SOX22) is a member of the SRY-related high-mobility group box (SOX) family of transcription factors. In humans, the canonical SOX12 protein has a length of 315 amino acid residues and a molecular weight of 34.1 kDa . SOX12 belongs to the SoxC group along with Sox4 and Sox11, sharing structural and functional similarities .

SOX12 is predominantly localized in the nucleus and functions as a transcription factor that binds to DNA at the consensus sequence 5'-ACCAAAG-3' . Its expression is most abundant in the central nervous system (CNS), but it has been detected in various tissues and plays roles in:

• Cell fate decisions in diverse developmental processes

• Differentiation and maintenance of several cell types

• Organogenesis through supporting cell survival in developing tissues like the neural tube, branchial arches, and somites (in redundancy with SOX4 and SOX11)

• T-cell differentiation, particularly in promoting FOXP3 transcription and regulatory T cell development

What types of SOX12 antibodies are available for research applications?

SOX12 antibodies are available in several formats to accommodate different experimental needs:

Most commercially available SOX12 antibodies show reactivity with human and mouse samples, with some also cross-reacting with rat and other species . When selecting an antibody, researchers should consider the specific epitope region (e.g., C-terminal region antibodies) and validated applications for their experimental system .

What are the most common applications for SOX12 antibodies in research?

SOX12 antibodies have been validated for multiple experimental techniques:

• Western Blot (WB): Most widely used application, typically with dilutions ranging from 1:500-1:2000. The observed molecular weight is approximately 35-40 kDa .

• Immunoprecipitation (IP): For protein-protein interaction studies.

• RNA Immunoprecipitation (RIP): For studying RNA-protein interactions.

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection.

• Immunofluorescence (IF): Recommended dilutions range from 0.25-2 μg/mL for cellular localization studies .

Each application may require specific optimization depending on the antibody and experimental system used .

How should I choose the appropriate SOX12 antibody for my specific research application?

Selecting the optimal SOX12 antibody requires consideration of several key factors:

• Experimental technique: Different applications require antibodies with specific validation. For example:

  • For Western blotting: Choose antibodies specifically validated for WB with demonstrated specificity at the expected molecular weight (35-40 kDa)

  • For immunofluorescence: Select antibodies that have been validated for subcellular localization in the nucleus

• Species reactivity: Match the antibody's validated species reactivity to your experimental model. Many SOX12 antibodies react with human and mouse samples, but reactivity with other species varies .

• Target region: Consider whether you need:

  • C-terminal targeting antibodies

  • N-terminal targeting antibodies

  • Full-length protein recognition

• Validation data: Review published literature and validation data where SOX12 antibodies have been used in knockout/knockdown experiments to confirm specificity .

• Cross-reactivity: Consider potential cross-reactivity with other SOX family members, especially SOX4 and SOX11 which share structural similarities with SOX12 .

What are the optimal protocols for SOX12 detection by Western blotting?

For optimal SOX12 detection by Western blotting, follow these methodological guidelines:

• Sample preparation:

  • For tissues: Mouse testis, mouse brain, and human cancer cell lines (e.g., BxPC-3) have demonstrated good SOX12 expression

  • Prepare samples in standard lysis buffer containing protease inhibitors

  • Ensure complete denaturation by heating samples at 95°C for 5 minutes in reducing sample buffer

• Gel electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal resolution of the 35-40 kDa SOX12 protein

  • Transfer to PVDF or nitrocellulose membranes at 100V for 1-2 hours or 30V overnight

• Blocking and antibody incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Incubate with primary SOX12 antibody at dilutions ranging from 1:500-1:2000

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3-5 times with TBST, 5 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

  • Wash 3-5 times with TBST

• Detection:

  • Use enhanced chemiluminescence (ECL) detection reagents

  • Expected molecular weight: 35-40 kDa

• Controls:

  • Positive controls: Mouse testis tissue, mouse brain tissue, BxPC-3 cells

  • Negative controls: Tissues or cells with SOX12 knockdown/knockout

How can I validate the specificity of a SOX12 antibody?

Validating SOX12 antibody specificity is crucial to ensure reliable experimental results. Implement these strategies:

• Genetic approaches:

  • Use SOX12 knockdown or knockout samples as negative controls

  • Multiple published studies have utilized SOX12 shRNA transduced cells to confirm antibody specificity

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunogenic peptide

  • Compare signal between blocked and unblocked antibody - specific signals should be eliminated or significantly reduced

• Multiple antibody validation:

  • Compare results using antibodies targeting different epitopes of SOX12

  • Concordant results with independent antibodies suggest specificity

• Molecular weight verification:

  • Confirm detection at the expected molecular weight (35-40 kDa for SOX12)

  • Check for absence of non-specific bands

• Cross-species reactivity:

  • If the antibody claims multi-species reactivity, test across those species

  • Verify conservation of the epitope sequence across species

• Recombinant protein control:

  • Use purified recombinant SOX12 protein as a positive control

  • Antibodies should specifically detect this protein

How is SOX12 involved in cancer progression and what methodologies are best for investigating this role?

SOX12 has been implicated in multiple cancer types, with particularly strong evidence in hepatocellular carcinoma (HCC) and acute myeloid leukemia (AML). Research approaches to investigate this role include:

• Expression analysis in cancer tissues:

  • Immunohistochemistry (IHC) studies have shown SOX12 expression is positively correlated with Foxp3 (Treg marker) and CD11b expression but negatively correlated with CD8 (CD8+ T-cell marker) in HCC tissues

  • Patients with positive SOX12 expression show more aggressive tumor characteristics and poorer prognosis

• Functional studies using genetic manipulation:

  • SOX12 knockdown in THP1 cells (AML cell line) demonstrated:

    • Reduced cell proliferation

    • Cell cycle arrest at G1 phase

    • Reduced colony formation

    • Diminished leukemia progression in NOD/SCID mice transplantation models

  • In HCC models, SOX12 overexpression:

    • Increased intratumoral regulatory T-cell infiltration

    • Decreased CD8+ T-cell infiltration

    • Accelerated metastasis

• Mechanistic investigations:

  • SOX12 has been shown to transcriptionally activate CCL22 expression, promoting Treg recruitment

  • SOX12 upregulates CD274 (PD-L1) expression, suppressing CD8+ T-cell function

  • In AML, SOX12 knockdown reduced β-catenin expression and TCF/Wnt activity

• In vivo models:

  • Hepatocyte-specific SOX12 knockout attenuated DEN/CCl4-induced HCC progression

  • Hepatocyte-specific SOX12 knock-in accelerated these effects

• Therapeutic targeting approaches:

  • Combined inhibition of CCR4 (receptor for CCL22) with anti-PD-L1 showed enhanced antitumor effects in HCC models with SOX12 overexpression

  • TGFβR1 inhibitor galunisertib combined with anti-PD-L1 exhibited synergistic effects

What are the methodological considerations for investigating SOX12's transcriptional activity?

SOX12 functions as a transcription factor, binding to the consensus sequence 5'-ACCAAAG-3' . To investigate its transcriptional activity:

• Chromatin Immunoprecipitation (ChIP) assays:

  • Use validated SOX12 antibodies for immunoprecipitation of DNA-protein complexes

  • Design primers targeting suspected SOX12 binding sites in promoter regions

  • Optimize sonication conditions to generate 200-500 bp DNA fragments

  • Include positive controls (known SOX12 targets) and negative controls (non-target regions)

  • Validate findings with ChIP-seq for genome-wide binding site identification

• Reporter gene assays:

  • Design luciferase reporter constructs containing promoter regions with putative SOX12 binding sites

  • Generate mutated binding site constructs as controls

  • Co-transfect reporter constructs with SOX12 expression plasmids

  • Measure luciferase activity to quantify transcriptional activation

• Gene expression analysis after SOX12 modulation:

  • Perform RNA-seq or qRT-PCR following SOX12 overexpression or knockdown

  • Focus on genes with putative SOX12 binding sites in their regulatory regions

  • Validate direct targets by combining with ChIP data

• Co-immunoprecipitation studies:

  • Identify transcriptional co-factors that interact with SOX12

  • SOX12 has been shown to bind cooperatively with POU3F2/BRN2 or POU3F1/OCT6 to enhance transcriptional activation

• DNA binding studies:

  • Electrophoretic mobility shift assays (EMSA) to confirm direct binding to target sequences

  • In vitro studies with recombinant SOX12 protein and oligonucleotides containing consensus binding sites

What is the relationship between SOX12 and immune regulation, and how can this be experimentally investigated?

Recent research has revealed SOX12's role in immune regulation, particularly in the context of cancer. Methodological approaches to investigate this include:

• Tumor microenvironment analysis:

  • Flow cytometry to quantify immune cell populations (Tregs, CD8+ T cells, MDSCs) in SOX12-manipulated tumor models

  • Multiplex immunohistochemistry to visualize spatial relationships between SOX12-expressing cells and immune cells

  • Single-cell RNA sequencing to capture heterogeneity in immune populations

• Mechanisms of Treg recruitment and activation:

  • SOX12 transcriptionally activates CCL22, promoting CCR4+ Treg recruitment

  • Chemotaxis assays using conditioned media from SOX12-overexpressing cells

  • T-cell suppression assays to assess functional changes in Tregs

• PD-L1 regulation:

  • SOX12 upregulates PD-L1 (CD274) expression, contributing to T-cell exhaustion

  • Flow cytometry and immunoblotting to measure PD-L1 expression

  • ChIP assays to confirm direct transcriptional regulation of CD274 by SOX12

• Therapeutic intervention studies:

  • Combination treatments with immune checkpoint inhibitors (anti-PD-L1) and CCR4 inhibitors or TGFβR1 inhibitors in SOX12-overexpressing tumors

  • Assessment of tumor growth, metastasis, and immune infiltration

• TGF-β signaling connection:

  • TGF-β1 upregulates SOX12 through the Smad2/3/4 signaling pathway

  • Immunoblotting and qRT-PCR to assess pathway activation

  • Use of pathway inhibitors to disrupt this signaling axis

What are common challenges in SOX12 antibody-based experiments and how can they be addressed?

Researchers may encounter several challenges when working with SOX12 antibodies:

• Cross-reactivity with other SOX family members:

  • SOX12 shares structural similarities with SOX4 and SOX11

  • Solution: Validate antibody specificity using SOX12 knockout/knockdown controls

  • Perform parallel experiments with specific antibodies against SOX4 and SOX11

  • Select antibodies targeting unique regions of SOX12

• Low endogenous expression levels:

  • Solution: Use positive control samples known to express SOX12 (mouse testis, mouse brain, BxPC-3 cells)

  • Consider enrichment techniques like nuclear extraction (since SOX12 is nuclear-localized)

  • Optimize antibody concentration and incubation conditions

• Background signal in immunofluorescence:

  • Solution: Optimize fixation methods (paraformaldehyde vs. methanol)

  • Increase blocking time/concentration

  • Use detergents (Triton X-100, 0.1-0.5%) to improve nuclear penetration

  • Try antigen retrieval methods if using fixed tissues

• Multiple bands in Western blot:

  • Solution: Optimize sample preparation (fresh preparation, complete denaturation)

  • Test different antibody dilutions (1:500-1:2000 recommended range)

  • Include phosphatase inhibitors to account for potential post-translational modifications

  • Expected molecular weight is 35-40 kDa

• Inconsistent results across different lot numbers:

  • Solution: Maintain detailed records of antibody lot numbers

  • Re-validate new lots using positive controls

  • Consider switching to recombinant antibodies for greater consistency

How should I design experiments to study SOX12 function in different biological contexts?

Designing robust experiments to investigate SOX12 function requires careful consideration of several factors:

• Model system selection:

  • Cell lines: Choose models with endogenous SOX12 expression (BxPC-3, THP1) or introduce SOX12 expression constructs

  • Animal models: Consider hepatocyte-specific SOX12 knockout or knock-in mouse models for HCC studies

  • Primary tissue: Human samples can be stratified by SOX12 expression levels

• Genetic manipulation approaches:

  • Transient vs. stable expression/knockdown:

    • Transient: Quick results but variable efficiency

    • Stable: More consistent results for long-term studies

  • CRISPR/Cas9 for complete knockout

  • Inducible systems for temporal control of SOX12 expression

• Functional readouts:

  • Proliferation assays (SOX12 knockdown reduces cell proliferation in THP1 cells)

  • Cell cycle analysis (SOX12 knockdown induces G1 arrest)

  • Colony formation assays

  • Migration and invasion assays (particularly for HCC studies)

  • In vivo tumor growth and metastasis models

• Pathway analysis:

  • Wnt/β-catenin pathway (SOX12 regulates β-catenin expression in AML)

  • TGF-β signaling (TGF-β1 upregulates SOX12 via Smad2/3/4)

  • Immunoregulatory pathways (CCL22/CCR4 axis, PD-L1/PD-1 pathway)

• Context-dependent effects:

  • Cancer vs. normal development contexts

  • Tissue-specific effects (CNS vs. immune system)

  • Design experiments to capture these contextual differences

How can contradictory findings regarding SOX12 function be reconciled and experimentally addressed?

Researchers may encounter seemingly contradictory results about SOX12 function across different experimental systems. To address these discrepancies:

• Systematic comparison of experimental conditions:

  • Create a comprehensive table comparing:

    • Cell/tissue types used

    • SOX12 expression levels

    • Experimental techniques

    • Readout parameters

  • Identify potential context-dependent effects

• Context-specific effects investigation:

  • SOX12 may have different partners in different cell types

  • Perform co-immunoprecipitation studies to identify cell-type-specific interacting proteins

  • Compare SOX12 genomic binding sites across different cell types using ChIP-seq

• Technical validation:

  • Reproduce key findings using multiple technical approaches

  • For example, validate protein-level changes with multiple antibodies

  • Confirm functional effects with both gain- and loss-of-function studies

• Dosage effects consideration:

  • Test effects of varying SOX12 expression levels

  • Create dose-response curves for SOX12-mediated effects

• Post-translational modifications assessment:

  • Investigate whether SOX12 undergoes context-specific modifications

  • Phosphorylation, acetylation, or other PTMs may alter SOX12 function

  • Use mass spectrometry to identify modifications

  • Create mutants to mimic or prevent specific modifications

• Temporal dynamics studies:

  • Examine acute vs. chronic effects of SOX12 modulation

  • Use inducible systems to control timing of expression changes

• Meta-analysis approach:

  • Pool data from multiple studies

  • Identify consistent patterns and outliers

  • Generate new hypotheses to explain discrepancies